20240423-133506
Home / About Us
0+
National innovation team in priority area
0+
Core technology platforms
0+
Launched drug products
0+
National Major Scientific and Technological Special Projects for Significant New Drug Development
After 14-year development, the long-acting interferon drug product developed by Amoytop Biotech, Pegbing (Mipeginterferon alfa-2b), a national class-1 new drug, was approved in China in 2016. Pegbing is the first 40kD Y-shape branded PEG-modified interferon alfa-2b injection in the world. With a special structure under complete patent protection, it has broken the monopoly of foreign products in treatment of viral hepatitis, and was awarded with “2016 Top 10 China Medicinal Biotech Progress” by China Medicinal Biotechnology Association.

Recently, with the idea of “clinical cure” in chronic hepatitis B treatment field gradually recognized by hepatitis specialists and clinicians, Amoytop Biotech has supported and conducted a series of research projects aiming to improve CHB clinical cure level, including CHB clinical cure projects listed in the National Major Scientific and Technological Special Projects during the “13th Five-year Plan” period, exploratory researches on the application and optimization of chronic hepatitis B clinical cure, and relevant confirmatory clinical trials. Through continuous exploration and accumulation, Amoytop Biotech is devoted to being the leader in the field of CHB clinical cure based on pegylated interferon alfa-2b.


"Specialized in R&D and production of recombinant protein drugs, committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy"

Company Culture

Vision

To be a Leading International Biopharmaceutical Company in China

Mission

Devoted to Constant Innovation in Biopharmaceutical Field for a Better and Healthier Life for Human

Core Value

Responsibility丨Fairness丨Performance丨Win-Win

Milestones

Awards and Honors

  • Social Responsibility
    ​​​​​​​Great ships require deep waters; swift horses cover great distances. “Realizing the value of technology and knowledge by transforming them into products and services to benefit patients” is the initial mission and intention insisted on by Amoytop Biotech. As a pharmaceutical enterprise, promoting the development of the biomedical industry and providing a healthier life for more patients are the main social responsibility of Amoytop Biotech.
Facebook
Twitter
LinkedIn
Instagram
WELCOME
Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
Leave a Message
Get In Touch